CANCER PREVENTION AND CONTROL PROGRAM The UNC Lineberger Cancer Prevention and Control Program focuses on the development, evaluation, and dissemination of evidence-based interventions and policy approaches to improve cancer outcomes in North Carolina and beyond. Our program is comprised of 56 program members and fosters strong collaborations between faculty from the six schools; Schools of Medicine, Public Health, Nursing, Pharmacy, Media and Journalism, and the College of Arts and Sciences and 28 departments. The CPC program has four broad themes: (1) Implementing health promotion interventions to reduce cancer risk factors; (2) Developing cancer communication strategies to improve cancer prevention and control; (3) Improving quality of cancer care and long-term outcomes for cancer survivors; and (4) Studying patterns of cancer care, screening, and prevention to inform interventions and policy initiatives that improve cancer outcomes. Eliminating cancer health disparities is a cross-cutting theme of our program. Highlights of our nationally recognized research by program investigators include: tobacco control policy research on the design and efficacy of graphic cigarette warning labels that is guiding FDA policy; research on sales and marketing of electronic cigarettes, including interventions to prevent adolescent e-cigarette use; research on digital and mobile interventions for diet, obesity, physical activity, and symptom management with particular focus on disadvantaged populations and cancer survivors; novel patient-reported outcomes studies that inform national policy; and implementing interventions in our Catchment area of North Carolina focused on eliminating disparities in access and outcomes. The Program is led by Dr. Kurt M. Ribisl, a behavioral scientist, and Dr. Ethan Basch, a medical oncologist and health services researcher. Program members are PIs of three NCI funded pre- and post-doctoral training grants. The Program adds value in terms of integrative activities and opportunities for intra- and cross-program collaboration; professional development and networking support for junior faculty CPC members; access to shared resources such as the Communications for Health Applications and Interventions, Biostatistics, and Patient-Reported Outcomes Core; as well as space, seminars, retreats, training, and education. Since our last renewal, UNC Lineberger has benefited the Program through strong support for infrastructure, faculty recruitments, extensive use of shared resources, and providing developmental funds as befits one of three major UNC Lineberger strategic directions, ?Optimizing Cancer Outcomes in North Carolina.? During the last funding period, program members have published 1359 cancer-related articles, 26% were intra-programmatic and 19% were inter-programmatic (38% collaborative). In 2019, our program members held grants totaling $18.9M (direct cost) in cancer-relevant extramural funding, including $6.8M (direct costs) from the NCI and $8.9M in other peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089818
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Cameron, Jennifer E; Rositch, Anne F; Vielot, Nadja A et al. (2018) Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers. Sex Transm Dis 45:666-672
Lim, Joseph K; Liapakis, Ann Marie; Shiffman, Mitchell L et al. (2018) Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 16:1811-1819.e4
Wang, Gary P; Terrault, Norah; Reeves, Jacqueline D et al. (2018) Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep 8:3199
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Lianga, Noel; Doré, Carole; Kennedy, Erin K et al. (2018) Cdk1 phosphorylation of Esp1/Separase functions with PP2A and Slk19 to regulate pericentric Cohesin and anaphase onset. PLoS Genet 14:e1007029
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Agle, Kimberle; Vincent, Benjamin G; Piper, Clint et al. (2018) Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD. Blood 132:435-447
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Stanley, Christopher C; van der Gronde, Toon; Westmoreland, Kate D et al. (2018) Risk factors and reasons for treatment abandonment among children with lymphoma in Malawi. Support Care Cancer 26:967-973

Showing the most recent 10 out of 1525 publications